Natera Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (NASDAQ: ADGI) announced th

Natera (NASDAQ:NTRA) is scheduled to announce Q4 earnings results on Thursday, February 24th, after market close.The consensus EPS Estimate is -$1.31 (-47.2% Y/Y) and the consensus…

Teladoc (TDOC) delivered earnings and revenue surprises of 88.14% and 1.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Over the past three months, shares of Natera (NASDAQ: NTRA ) decreased by 34.50%. Before we understand the importance of debt, let us look at how much debt Natera has. Check out this: Insiders Buy More Than $170M Of 4 Stocks Natera''s Debt According to the Natera''s most recent balance sheet as reported on November 5, 2021, total debt is at $330.13 million, with $280.08 million in long-term debt and $50.05 million in current debt. Adjusting for $95.10 million in cash-equivalents, the company has a net debt of $235.03 million. Let''s define some of the terms we used in the paragraph above. Current debt is the portion of a company''s debt which Full story available on Benzinga.com

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug A

AUSTIN, Texas, Feb. 17, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2021, after the market close on February 24, 2022. Natera will host a…

Natera (NTRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AUSTIN, Texas, Feb. 17, 2022 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year end

Natera (NTRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AUSTIN, Texas, Feb. 15, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman, chief executive officer, and Mike Brophy, chie

Related Stocks: PFE , NTRA , UNP , S , S , LSCC , NFLX , SPSC , ZWS , POWI , LAND , HLIO , EVBG , RETA , CDLX , RPAY , ALLK ,

NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Natera, Inc. (Natera or the Company) (NASDAQ: NTRA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

AUSTIN, Texas, Jan. 19, 2022 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced the company, along with its collaborators, will pr

Natera Inc (NTRA) shares closed today at 0.4% above its 52 week low of $74.87, giving the company a market cap of $7B. The stock is currently down 19.5% year-to-date, down 32.4% over the past 12 months, and up 554.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 23.5% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 285.3% The company's stock price performance over the past 12 months lags the peer average by -288.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.